利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

65 条记录 (耗时 0.036 秒)

    Method for treating and/or preventing retinal diseases with sustained release corticosteroids
    21.
    发明申请
    Method for treating and/or preventing retinal diseases with sustained release corticosteroids 审中-公开
    用持续释放的皮质类固醇治疗和/或预防视网膜疾病的方法

    公开(公告)号：US20070098760A1

    公开(公告)日：2007-05-03

    申请号：US11635161

    申请日：2006-12-07

    申请人： Hong Guo ,  Paul Ashton

    发明人： Hong Guo ,  Paul Ashton

    IPC分类号： A61K31/573 ,  A61F2/02

    CPC分类号： A61K31/573 ,  A61K9/0051

    摘要： The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.

    摘要翻译： 本发明涉及向眼后段施用皮质类固醇的方法。 在该方法中，植入持续释放装置以将皮质类固醇递送至眼睛。 在皮质类固醇释放期间，皮质类固醇水溶液的浓度仍然低于玻璃体皮质类固醇浓度。

    Network management system having historical virtual catalog snapshots for overview of historical changes to files distributively stored across network domain
    24.
    发明授权
    Network management system having historical virtual catalog snapshots for overview of historical changes to files distributively stored across network domain 失效
    具有历史虚拟目录快照的网络管理系统，用于概述跨网域分布式存储的文件的历史更改

    公开(公告)号：US5678042A

    公开(公告)日：1997-10-14

    申请号：US590528

    申请日：1996-01-24

    申请人： Thomas Pisello ,  David Crossmier ,  Paul Ashton

    发明人： Thomas Pisello ,  David Crossmier ,  Paul Ashton

    IPC分类号： G06F12/00 ,  G06F13/00 ,  G06F17/30 ,  G06F7/00 ,  G06F7/06

    CPC分类号： G06F17/30126 ,  Y10S707/922 ,  Y10S707/951 ,  Y10S707/954 ,  Y10S707/959 ,  Y10S707/99937

    摘要： A network management system includes a domain administrating server (DAS) that stores a virtual catalog representing an overview of all files distributively stored across a network domain currently or in the past. The current and historical file information is used for assisting in auditing or locating files located anywhere in the domain. The current file information is used for assisting in transferring files across the domain. The domain administrating server (DAS) also includes a rule-base driven artificial administrator for monitoring and reacting to domain-wide alert reports and for detecting problematic trends in domain-wide performance based on information collected from the network domain.

    摘要翻译： 网络管理系统包括域管理服务器（DAS），域管理服务器（DAS）存储表示当前或过去通过网络域分布式存储的所有文件的概述的虚拟目录。 当前和历史文件信息用于协助审核或定位位于域中任何位置的文件。 当前文件信息用于协助跨域传输文件。 域管理服务器（DAS）还包括基于规则的驱动人造管理员，用于监视和响应域范围的警报报告，并根据从网络域收集的信息来检测全域性能的问题趋势。

    Compositions and Methods for Controlled Release of Agents
    25.
    发明申请
    Compositions and Methods for Controlled Release of Agents 审中-公开
    药剂控制释放的组成和方法

    公开(公告)号：US20160075776A1

    公开(公告)日：2016-03-17

    申请号：US14855946

    申请日：2015-09-16

    申请人： Paul Ashton ,  Hong Guo ,  Leigh T. Canham ,  Dinesh Nadarassan

    发明人： Paul Ashton ,  Hong Guo ,  Leigh T. Canham ,  Dinesh Nadarassan

    IPC分类号： C07K16/24 ,  A61K9/00 ,  C07K16/22 ,  A61K38/22 ,  A61K9/16 ,  C07K14/715

    CPC分类号： A61K38/22 ,  A61K9/0051 ,  A61K47/02 ,  C07K14/7151 ,  C07K2319/30

    摘要： This invention discloses reservoirs, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies. The reservoirs may comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The reservoir may be used in vitro or in vivo to maintain an equilibrium concentration of a therapeutic agent over an intended period of time such as over multiple days, weeks, months, or years. Additionally, the reservoir may be reloaded with additional therapeutic agent. These reservoirs may be used for treating or preventing conditions of a subject such as chronic diseases.

    摘要翻译： 本发明公开了诸如用于递送治疗剂的植入物，特别是大分子如蛋白质和抗体的储库。 储存器可以包含浸渍有治疗剂的多孔硅基载体材料。 储存器可以在体外或体内使用以维持治疗剂在预期的时间段内的平衡浓度，例如超过几天，几周，几个月或几年。 此外，储存器可以用另外的治疗剂重新装载。 这些储存器可用于治疗或预防受试者例如慢性疾病的病症。

    METHODS OF TREATING MACULAR EDEMA USING ANTIEDEMA THERAPEUTICS
    27.
    发明申请
    METHODS OF TREATING MACULAR EDEMA USING ANTIEDEMA THERAPEUTICS 审中-公开
    使用抗精神病药治疗恶性肿瘤的方法

    公开(公告)号：US20120207682A1

    公开(公告)日：2012-08-16

    申请号：US13372302

    申请日：2012-02-13

    申请人： Paul Ashton

    发明人： Paul Ashton

    IPC分类号： A61K31/58 ,  A61B3/032 ,  A61P27/02 ,  A61K31/713 ,  A61K9/14 ,  A61K49/00 ,  A61B3/028 ,  A61K39/395

    CPC分类号： A61K31/58 ,  A61K9/0051 ,  A61K45/06 ,  A61K47/32

    摘要： The invention provides methods of treating macular edema in a patient that include determining whether the patient has been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time. If the patient has been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time, the method of treatment includes administering a therapeutically effective amount of an AED to the patient. If the patient has not been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time, the method of treatment optionally includes treating the patient with a therapy other than an AED. The invention further provides methods of treating macular edema in a patient using methods of and devices for administering an AED.

    摘要翻译： 本发明提供了治疗患者黄斑水肿的方法，其包括确定患者是否已被诊断患有或已经经历了预定时间段的黄斑水肿症状。 如果患者已被诊断出患有或经历了黄斑水肿的症状达预定时间段，治疗方法包括向患者施用治疗有效量的AED。 如果患者在预定时间段内没有被诊断出患有黄斑水肿或已经经历了黄斑水肿的症状，则治疗方法任选地包括用不同于AED的治疗来治疗患者。 本发明还提供使用方法和用于施用AED的装置治疗患者的黄斑水肿的方法。

    POLYMERIC GEL DELIVERY SYSTEM FOR PHARMACEUTICALS
    28.
    发明申请
    POLYMERIC GEL DELIVERY SYSTEM FOR PHARMACEUTICALS 审中-公开
    用于药物的聚合物凝胶输送系统

    公开(公告)号：US20120195934A1

    公开(公告)日：2012-08-02

    申请号：US13370106

    申请日：2012-02-09

    申请人： Paul Ashton ,  Jianbing Chen

    发明人： Paul Ashton ,  Jianbing Chen

    IPC分类号： A61K9/00 ,  A61K38/00 ,  A61K31/56 ,  A61K31/513 ,  A61K31/439 ,  A61P29/00 ,  A61P19/02 ,  A61P31/00 ,  A61P31/10 ,  A61P31/12 ,  A61P27/06 ,  A61P37/02 ,  A61P41/00 ,  A61P3/00 ,  A61P35/00 ,  A61K47/00

    CPC分类号： A61K9/0024 ,  A61K9/0019 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/205 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/55

    摘要： Implantable, injectable, insertable, or otherwise administrable compositions that form hydrogels when implanted, injected, inserted, or administered into or onto living tissues comprise a pharmaceutically effective compound wherein the pharmaceutically effective compound is a codrug, or pharmaceutically acceptable salt or prodrug thereof in admixture with a hydrogel-forming compound. The pharmaceutically effective compound may be any compound that is soluble in bodily fluids, or that forms bodily fluid-soluble adducts when exposed to bodily fluids. Exemplary compounds include analgesic, anti-inflammatory and antibiotic compounds. The hydrogel-forming compound is a biologically tolerated substance that forms a hydrogel upon exposure to bodily fluids, such as the interstitial fluid surrounding or within a joint.

    摘要翻译： 当植入，注射，可插入或以其他方式施用的组合物在植入，注射，插入或施用于生物组织中或其上时形成水凝胶包含药学上有效的化合物，其中药学上有效的化合物是其药物或其药学上可接受的盐或前药的混合物 与水凝胶形成化合物。 药学上有效的化合物可以是可溶于体液的任何化合物，或当暴露于体液时形成体液可溶性加合物。 示例性化合物包括止痛剂，抗炎剂和抗生素化合物。 形成水凝胶的化合物是一种生物耐受物质，其在暴露于体液如围绕或在关节内的间质液体时形成水凝胶。